Aspiriant LLC Sells 106 Shares of Clorox Co (NYSE:CLX)

Aspiriant LLC lessened its holdings in shares of Clorox Co (NYSE:CLX) by 6.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,494 shares of the company’s stock after selling 106 shares during the quarter. Aspiriant LLC’s holdings in Clorox were worth $227,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Alps Advisors Inc. acquired a new position in shares of Clorox in the third quarter valued at approximately $356,000. SG Americas Securities LLC boosted its stake in shares of Clorox by 94.7% in the third quarter. SG Americas Securities LLC now owns 26,751 shares of the company’s stock valued at $4,063,000 after buying an additional 13,008 shares during the period. First Trust Advisors LP boosted its stake in shares of Clorox by 8.6% in the third quarter. First Trust Advisors LP now owns 271,765 shares of the company’s stock valued at $41,273,000 after buying an additional 21,611 shares during the period. Unigestion Holding SA boosted its stake in shares of Clorox by 7.8% in the third quarter. Unigestion Holding SA now owns 49,229 shares of the company’s stock valued at $7,476,000 after buying an additional 3,559 shares during the period. Finally, Donaldson Capital Management LLC bought a new stake in shares of Clorox in the third quarter valued at approximately $19,829,000. 78.42% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP Michael R. Costello sold 3,225 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $161.34, for a total value of $520,321.50. Following the completion of the transaction, the senior vice president now directly owns 29,669 shares in the company, valued at approximately $4,786,796.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew J. Mowery sold 5,648 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $146.29, for a total value of $826,245.92. Following the completion of the transaction, the senior vice president now owns 15,920 shares of the company’s stock, valued at $2,328,936.80. The disclosure for this sale can be found here. Insiders sold a total of 15,870 shares of company stock valued at $2,484,000 over the last quarter. 1.14% of the stock is owned by corporate insiders.

CLX has been the subject of several recent research reports. Cfra cut Clorox from a “hold” rating to a “sell” rating in a research note on Friday, November 1st. Royal Bank of Canada boosted their price target on Clorox to $161.00 and gave the company a “sector perform” rating in a research note on Friday, August 2nd. Credit Suisse Group cut their price target on Clorox from $172.00 to $168.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Wells Fargo & Co reiterated a “hold” rating and issued a $150.00 price target on shares of Clorox in a research note on Wednesday, October 2nd. Finally, Morgan Stanley restated an “underweight” rating and set a $134.00 target price (down from $144.00) on shares of Clorox in a research note on Monday, September 30th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $152.00.

NYSE CLX opened at $148.00 on Friday. The business has a fifty day moving average price of $149.93 and a two-hundred day moving average price of $154.33. The company has a debt-to-equity ratio of 4.69, a current ratio of 0.87 and a quick ratio of 0.52. Clorox Co has a fifty-two week low of $143.58 and a fifty-two week high of $167.70. The stock has a market capitalization of $18.55 billion, a PE ratio of 23.42, a PEG ratio of 4.73 and a beta of 0.38.

Clorox (NYSE:CLX) last released its earnings results on Thursday, October 31st. The company reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.05. Clorox had a return on equity of 123.56% and a net margin of 13.20%. The firm had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the prior year, the company earned $1.62 earnings per share. The company’s quarterly revenue was down 3.6% on a year-over-year basis. As a group, sell-side analysts expect that Clorox Co will post 6.16 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Wednesday, October 30th will be paid a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date is Tuesday, October 29th. Clorox’s payout ratio is 67.09%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: What is the cash asset ratio?

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.